RADPHARM DMSA powder for injection

国家: 澳大利亚

语言: 英文

来源: Department of Health (Therapeutic Goods Administration)

有效成分:

succimer, Quantity: 1 mg

可用日期:

Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific

INN（国际名称）:

Succimer

药物剂型:

Injection, powder for

组成:

Excipient Ingredients: inositol; ascorbic acid; stannous chloride

给药途径:

Intravenous

每包单位数:

5x8mL vials

处方类型:

Not scheduled. Not considered by committee

疗效迹象:

INDICATIONS AS AT 25 SEPTEMBER 1996: Technetium (99mTc) succimer may be used as a static renal imaging pharmaceutical and is particularly suited for evaluation of renal cortex, deliniation of renal space occupying lesions, determination of intrarenal function, distribution and identification of ectopic renal sites.

產品總結:

Visual Identification: Lyophilised white powder; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 1 Years; Container Temperature: Store at 2 to 8 degrees Celsius

授权状态:

Registered

授权日期:

1991-09-05

资料单张

RADPHARM
L4.2
SCIENTIFIC
DMSA RADPHARM
KIT FOR THE PREPARATION OF TECHNETIUM[
99M
TC] SUCCIMER INJECTION FOR RENAL
IMAGING
PRODUCT DATA
AUST R 14326
DESCRIPTION
This Kit consists of sterile, pyrogen free lyophilised ingredients
which need
reconstitution with sodium pertechnetate[
99m
Tc] injection to produce a
technetium[
99m
Tc] succimer complex suitable for renal imaging.
The precise structure of the technetium[
99m
Tc] succimer complex is
not known at this time.
Technetium[
99m
Tc] succimer is a diagnostic pharmaceutical administered
by intravenous injection.
CONTENTS AND PRESENTATION
DMSA Radpharm is supplied as a carton of 5 sterile, pyrogen free,
vacuum
sealed multidose 8 mL vials.
Each vial contains 1 mg succimer (_meso-_2,3-dimercaptosuccinic acid),
0.4 mg stannous chloride anhydrous, 0.7 mg ascorbic acid and 50.0 mg
inositol as a lyophilised powder.
The product contains no preservatives.
PHYSICAL CHARACTERISTICS OF TECHNETIUM-99M
Technetium-99m with a physical half life of 6 hours decays by isomeric
transition to technetium-99. Photons associated with this transition
that are
useful for detection and imaging studies are listed in Table 1.
Table 1. Principal Radiation Emission Data
Principal
Radiation
Mean Percent
per Disintegration
Mean Energy (keV)
Gamma-2
89.1
140.5
Reference: D A Weber et al. "MIRD: Radionuclide and decay schemes",
The Society of Nuclear Medicine Inc. New York, 1989.
Table 2. Physical Decay Chart for Technetium-99m
Hours
Fraction
Remaining
Hours
Fraction
Remaining
0
1.000
7
0.445
1
0.891
8
0.397
2
0.794
9
0.354
3
0.707
10
0.315
4
0.630
11
0.281
5
0.561
12
0.250
6
0.500
EXTERNAL RADIATION
The specific gamma ray constant for technetium-99m is 0.19 mGy/MBq-h
at 1 cm. The first half value thickness of lead (Pb) for
technetium-99m is
0.2 mm. Attenuation by lead is given in Table 3.
Table 3. Radiation Attenuation by Lead Shielding
Shield Thickness mm Pb
Coefficient of
Attenuation
0.95
0.1
1.8
0.01
2.7
0.001
3.6
0.0001
PHARMACOLOGY
Technetium[
99m
Tc] succimer exhibits insignificant glomerul